Subsequent Treatment after Transarterial Chemoembolization Failure/Refractoriness: A Review Based on Published Evidence  

作　　者：Shen Zhang Wan-Sheng Wang Bin-Yan Zhong Cai-Fang Ni 

机构地区：[1]Department of Interventional Radiology,The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China

出　　处：《Journal of Clinical and Translational Hepatology》2022年第4期740-747,共8页临床与转化肝病杂志（英文版）

基　　金：This study was supported by the National Natural Science Foundation of China(No.81901847);the Natural Science Foundation of Jiangsu Province(No.BK20190177);the Suzhou Science and Technology Youth Plan(No.KJXW2018003).

摘　　要：Transarterial chemoembolization(TACE)is widely applied for the treatment of hepatocellular carcinoma.Repeat TACE is often required in clinical practice because a satisfactory tumor response may not be achieved with a single session.However,repeated TACE procedures can impair liver function and increase treatment-related adverse events,all of which prompted the introduction of the concept of“TACE failure/refractoriness”.Mainly based on evidence from two retrospective studies conducted in Japan,sorafenib is recommended as the first choice for subsequent treatment after TACE failure/refractoriness.Several studies have investigated the outcomes of other subsequent treatments,including locoregional,other molecular targeted,anti-programmed death-1/anti-programed death ligand-1 therapies,and combination therapies after TACE failure/refractoriness.In this review,we summarize the up-to-date information about the outcomes of several subsequent treatment modalities after TACE failure/refractoriness.

关 键 词：Transarterial chemoemboization FAILURE REFRACTORINESS Subsequent treatment 

分 类 号：R735.7[医药卫生—肿瘤]